Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.32 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17961794 | 1.00 | SMN1; SMN2 (0.34) | SMN1; SMN2BRD4PDK1FKBP1AALDH1A1 | |
| SCHEMBL16579389 | 1.00 | SMN1; SMN2 (0.34) | SMN1; SMN2BRD4PDK1FKBP1AALDH1A1 | |
| SCHEMBL17961792 | 1.00 | SMN1; SMN2 (0.34) | SMN1; SMN2BRD4PDK1FKBP1AALDH1A1 | |
| SCHEMBL17972863 | 0.86 | FKBP1A (0.30) | FKBP1A | |
| SCHEMBL15878168 | 0.81 | OPRK1 (0.34) | SMN1; SMN2OPRK1 | |
| SCHEMBL20943538 | 0.81 | OPRK1 (0.34) | SMN1; SMN2OPRK1 | |
| SCHEMBL15878165 | 0.81 | OPRK1 (0.34) | SMN1; SMN2OPRK1 | |
| SCHEMBL15878162 | 0.81 | OPRK1 (0.34) | SMN1; SMN2OPRK1 | |
| SCHEMBL1700418 | 0.77 | SMN1; SMN2 (0.39) | SMN1; SMN2FKBP1AALDH1A1TP53GAA | |
| SCHEMBL1147987 | 0.77 | SMN1; SMN2 (0.39) | SMN1; SMN2FKBP1AALDH1A1TP53GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160221948-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-08-04 | — | — | US | disclosed |
| WO-2015037716-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | 住友化学株式会社 (JP) | 2015-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160221948-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-4, HRH4 | SMN1; SMN2 1489/4885BRD4 69/4885PDK1 4217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.